Australian researchers have identified the underlying mechanism for the rare and severe blood clotting condition known as Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), associated with adenovirus-vector COVID-19 vaccines. The findings point to an interaction between a specific protein within the vaccine's adenovirus vector and a rare human antibody, offering critical insights for future vaccine development and understanding autoimmune diseases.
Research Breakthrough: Unraveling VITT
A pivotal study, published in the New England Journal of Medicine, was led by Professor Tom Gordon and Dr. Jing Jing Wang from Flinders University. Their research pinpointed two primary factors contributing to the development of VITT:
- A protein located within the adenovirus vector utilized in the vaccines.
- A specific type of human antibody, produced by a small number of individuals, often referred to as a “forbidden clone,” which arises from a rare genetic mutation.
Dr. Jing Wang highlighted a potential solution, indicating that modifying or removing this specific adenovirus protein could potentially prevent such rare reactions in future vaccines. Professor Elizabeth Gardiner, scientific head of the National Platelet Referral and Research Centre, lauded the study's conclusions, describing them as "convincingly strong causal evidence."
The Dual Mechanism Behind VITT
The AstraZeneca vaccine, for example, employs an adenovirus vector to deliver genetic code that prompts an immune response against a COVID-19 viral fragment. Previous research in 2022 by Gordon and Wang had already observed that VITT patients possessed an unusual antibody that bound to a human protein called PF4, leading to blood clotting.
Subsequent observations by Canadian researchers found similar clotting syndromes in patients following natural adenovirus infections, suggesting a broader role for adenoviruses.
Dr. Wang's research further elucidated this connection:
- A protein deep within the adenovirus structure closely resembles human PF4.
- The vaccine prompts the immune system to produce antibodies against this adenovirus protein.
- In rare instances, particularly in individuals with certain genetic predispositions, one of these antibodies undergoes a mutation (such as K31E) that allows it to bind precisely to PF4, initiating the clotting process.
This mutated, self-reactive antibody is referred to as a "forbidden clone," which can multiply despite typical immune surveillance processes that would usually eliminate such self-reactive antibodies. Mass spectrometry was a key tool in this research, used to identify the molecular mimicry between the adenovirus protein and the PF4 target.
Incidence, Impact, and Patient Stories
In Australia, eight individuals tragically died due to VITT, including 34-year-old Katie Lees. The condition was observed in approximately two people per 100,000 vaccinated individuals, with symptoms typically appearing within a month of vaccination, or between 6 to 15 days post-vaccination in U.S. cases.
Globally, the Johnson & Johnson COVID-19 vaccine was authorized for emergency use in the U.S. in February 2021. However, the U.S. Food and Drug Administration (FDA) later requested its voluntary withdrawal due to reported VITT cases. In 2021, 15 cases of VITT were reported in the U.S., predominantly affecting women aged 18 to 59. Hundreds of cases have also been reported in Europe. The estimated death rate for VITT exceeds 20%, rising to 73% for patients experiencing a brain hemorrhage with blood clots in the brain.
Future Implications for Medicine
Researchers suggest these findings hold significant implications for future vaccine development. They may enable modifications to adenovirus vectors to prevent them from mimicking PF4, thereby mitigating the risk of VITT in future vaccines.
Furthermore, the study significantly contributes to the understanding of how a combination of environmental exposure and rare genetic mutations can lead to the development of autoimmune diseases.
Compensation and Lingering Concerns
Ian Lees, father of Katie Lees, conveyed concerns regarding the adequacy of discussions about VITT during the vaccine rollout. His family received $70,000 from the federal government’s Vaccine Claims Scheme.
A federal Department of Health spokesperson reported that the scheme, which has since closed, processed 4,369 claims out of 4,964 received, distributing a total of $62.3 million in compensation.